Showing 21-30 of 41 results for "".
- Remembering 9-11: A Dermatology Perspectivehttps://practicaldermatology.com/news/remembering-9-11-a-dermatology-perspective/2460522/New research takes a close look at dermatologic injuries and chronic skin conditions that have affected survivors and responders during the nearly two decades since the terrorist attacks on September 11, 2001. These chronic illnesses include sarcoidosis, autoimmune disease, ill-defined skin lesion…
- Vehicles, Infectious Disease, and Acne Updates from Day 2 at DERM2019https://practicaldermatology.com/news/vehicles-infectious-disease-and-acne-updates-from-day-2-at-derm2019/2460099/The DERM2019 NP/PA CME Conference continued to delight audiences with esteemed faculty presenters, including those who presented Friday, including April Armstrong, David Cohen, Kara Gooding, Joseph Gorelick, Julie Harper, Jayme Heim, George Keough, Leon Kircik, Kristine Kucera, Gilly Munavalli, Ted…
- Lilly: 5-Year Sustained Efficacy and Safety Results for Taltz in Plaque Psoriasis at WCDhttps://practicaldermatology.com/news/lilly-5-year-sustained-efficacy-and-safety-results-for-taltz-in-plaque-psoriasis-at-wcd/2460066/Patients with moderate- to severe plaque psoriasis who continued to receive Taltz® (ixekizumab) maintained high levels of skin clearance with no unexpected safety outcomes for up to five years of treatment, according to new data Eli Lilly and Company is presenting at the World Congress of Dermatolo…
- Ovation Science Appoints Medical Dermatology Advisory Boardhttps://practicaldermatology.com/news/ovation-science-appoints-medical-dermatology-advisory-board/2460008/Ovation Science, Inc. has entered into an exclusive agreement with Skincareguide.com Ltd., to act as the Company's Medical Dermatology Advisory Board for cannabis formulated products. The objective of the Medical Dermatology Advisory Board is to provide guidance, along with clinical, scientific, re…
- Seysara: Oral Antibiotic is First Approved for Dermatology in 40 Yearshttps://practicaldermatology.com/news/seysara-oral-antibiotic-is-first-approved-for-dermatology-in-40-years/2457584/Seysara (sarecycline), a new, first in class tetracycline-derived oral antibiotic, is now approved for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. Almirall, which recently acquired Seysara from Allergan, plans to launch…
- PD1 Blocker Shrinks Advanced Squamous Cell Skin Cancershttps://practicaldermatology.com/news/pd1-blocker-shrinks-advanced-squamous-cell-skin-cancers/2457737/A checkpoint inhibitor shrinks the tumors of nearly half of patients with an incurable, advanced form of squamous cell carcinoma, an international team reports in the New England Journal of Medicine. “These results mark a potential paradigm shift in the treatment of patients with advanced cutaneou…
- New Dermatologic Surgery Textbook by McGraw-Hill Enters Second Printing Less Than One Week After Publicationhttps://practicaldermatology.com/news/new-dermatologic-surgery-textbook-by-mcgraw-hill-enters-second-printing-less-than-one-week-after-publication/2457746/McGraw-Hill has just released Jonathan Kantor’s new 1,440-page textbook, Dermatologic Surgery, the most comprehensive and richly illustrated dermatologic surgery textbook ever published, and the first new major multimedia textbook in the field in 13 years. With section editors including John Albert…
- Botanical Dermatology Brand Kamedis Forms U.S. Medical Advisory Boardhttps://practicaldermatology.com/news/botanical-dermatology-brand-kamedis-forms-us-medical-advisory-board/2457834/Israeli-based Kamedis announced the formation of a U.S. medical advisory board. The members include: Zoe Draelos, MD, FAAD, a clinical and research dermatologist with a private solo practice in High Point, NC, who is also a Consulting Professor of Dermatology at Duke University. Dr. Draelos has a…
- Five-Year Data Show Sustained Efficacy, Safety for Cosentyxhttps://practicaldermatology.com/news/five-year-data-show-sustained-efficacy-safety-for-cosentyx/2458054/Novartis’ IL-17 blocker Cosentyx® (secukinumab) maintains PASI 90 and PASI 100 response rates at five years in patients with moderate to severe plaque psoriasis, according to new Phase III data. These data were presented for the first time at the 26th European Academy of Dermatology and Venereolog…
- The American Society for Laser Medicine and Surgery Names New Officershttps://practicaldermatology.com/news/the-american-society-for-laser-medicine-and-surgery-names-new-officers/2458185/The American Society for Laser Medicine and Surgery (ASLMS) introduced Mathew M. Avram, MD, JD, as its new President at the Annual Conference in April. Dr. Avram succeeds Kristen M. Kelly, MD, who now serves as the Society’s Past President. The 2017-18 ASLMS Executive Committee also includes Diete…